MedTrace Logo

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.

Conditions

  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Analgesia
  • Ketamine
  • Peripheral Nervous System Agents
  • Central Nervous System Depressants
  • Neurotransmitter Agents
  • Anti-Inflammatory Agents
  • Physiological Effects of Drugs
  • Sensory System Agents
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Depressive Symptoms

Interventions

DRUG

VTS-K

Proprietary oral formulation of 486mg aspirin and 80mg ketamine

Sponsors & Collaborators

  • Theresa Jacob, PhD, MPH

    lead OTHER

Principal Investigators

  • Theresa Jacob, PhD, MPH · Maimonides Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2024-05-17
Completion
2024-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615948 on ClinicalTrials.gov